ICU Medical Q2 revenue beat estimates on strength in Infusion Systems

ICU Medical

06/08/2026 21:36

Overview
U.S. medical device maker's Q2 revenue grew 1%, beating analyst expectations
Adjusted EPS and adjusted EBITDA for Q2 beat analyst expectations
Company raised full-year 2026 guidance for GAAP and adjusted EPS and adjusted EBITDA

Outlook
Company raises FY 2026 GAAP net income forecast to $73 mln-$83 mln from $26 mln-$44 mln
Company raises FY 2026 GAAP diluted EPS forecast to $2.89-$3.29 from $1.03-$1.74
Company raises FY 2026 adjusted EBITDA forecast to $415 mln-$435 mln from $400 mln-$430 mln
Company raises FY 2026 adjusted diluted EPS forecast to $8.60-$9.00 from $7.75-$8.45

Result Drivers
INFUSION SYSTEMS GROWTH - Co said Infusion Systems results were ahead of expectations, contributing to overall revenue growth
DIVESTITURE IMPACT - Year-over-year comparisons reflect the strategic divestiture of the IV Solutions business in May 2025, affecting Vital Care revenue
GROSS MARGIN IMPROVEMENT - Gross margin rose to 43% from 38% a year earlier; co did not specify exact drivers for the increase

Company press release: ID:nGNX1fCPGQ

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$551.68 mln
$533.43 mln (7 Analysts)
Q2 Adjusted EPS
Beat
$2.37
$1.91 (7 Analysts)
Q2 Gross Margin
 
43.00%
 
Q2 Gross Profit
 
$235.05 mln
 

Reuters Recommended Reads
Aug 6 - Becton Dickinson raises lower end of annual profit forecast on drug delivery devices strength
Aug 6 - Teleflex Q2 revenue rises 29%, beats analyst estimates
Aug 5 - Novanta beats Q2 revenue estimates on organic growth, raises 2026 guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)